New therapeutic approaches aiming to enhance NK cell activation by anti-HER2 agents are currently being evaluated [79], including the systemic treatment with recombinant cytokines [80], ADAM inhibitors [81], and the delivering of Toll-like receptor (TLR) ligands to the tumor site [82]. The gene discussed is ERBB2; the disease is neoplasm.